Skip to content

A human trial of Salacia reticulata extract on improvement of blood glucose

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Salacia reticulata extract on improvement of blood glucose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010960
Enrollment
100
Registered
2025-08-29
Start date
2024-04-22
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Salacia reticulata extract group: 2 times a day, 1 capsule once, before breakfast/dinner, a duration of 12 weeks(1,200 mg/day, Salacia reticulata extract for 500 mg/day) • pla

Sponsors

Daehan Chemtech
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adult men and women aged 19 years or older and 65 years or less at the screening test 2) Individuals with no history of diabetes treatment within three months prior to the screening test, whose fasting blood glucose at screening is between 100 mg/dL and 140 mg/dL, and whose postprandial blood glucose is between 140 mg/dL and 199 mg/dL 3) A person who, after hearing and fully understanding the detailed explanation of this trial, voluntarily decides to participate and agrees in writing to comply with the precautions

Exclusion criteria

Exclusion criteria: 1) Individuals who require diabetes treatment at the time of screening {HbA1c(Hemoglobin A1C) = 6.5%}. 2) Individuals with a body mass index (BMI) 3 times the upper limit of normal ? Serum creatinine > 2.0 mg/dL 10) Pregnant or breastfeeding women. 11) Women of childbearing potential who do not accept the practice of adequate contraception. 12) Individuals who is judged unsuitable for participation in the study by the director of the study due to diagnostic test results and other reasons.

Design outcomes

Primary

MeasureTime frame
Fasting glucose, Postprandial glucose

Secondary

MeasureTime frame
Fasting insuline, Postprandial insuline;AUC(Area Under the Curve), maximum concentration (Cmax), time to maximum concentration (Tmax);insulin-related markers;glucose-related markers;lipid metabolism markers

Countries

Korea, Republic of

Contacts

Public ContactPark Soo Jung

Woosuk University Korean Medicine Medical Center

taorgi@hanmail.net+82-63-220-8676

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Jun 29, 2026